Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
8 Results for "
DOT1L PROTAC
" in MedChemExpress (MCE) Product Catalog:
Products (8)
8 Results for "DOT1L PROTAC" in MCE Product Catalog:
Cat. No.: HY-173422
Target:
Research Areas:
MS2133 is a VHL-recruiting DOT1L PROTAC degrader. MS2133 possesses antiproliferative activity with a human DOT1L IC50 of 4.6 nM, forms a ternary complex with DOT1L and VHL E3 ligase to drive DOT1L ubiquitination and subsequent proteasomal degradation without affecting DOT1L mRNA transcription, inhibits the proliferation of mixed lineage leukemia-rearranged leukemia cells and downregulates H3K79Me2, restrains proliferation of both tumor and normal cells but lacks cytotoxicity against normal cells, and can be used for the research of mixed lineage leukemia-rearranged leukemia .
Cat. No.: HY-173423
Research Areas:
DOT1L ligand-1 is a DOT1L ligand. DOT1L ligand-1 can be used as a Ligands for Target Protein for PROTAC synthesis, such as MS2133 (HY-173422) .
Cat. No.: HY-153959
CAS No.: 2473270-96-9
Research Areas:
Thalidomide-O-amido-C11-COOH (compound IMiD acid 1) is an E3 ligase ligand and linker CRBN (Cereblon) conjugate. Thalidomide-O-amido-C11-COOH can be used to synthesize PROTAC that target the degradation of DOT1L .
Cat. No.: HY-181790
Research Areas:
DOT1L ligand-2 (Compound 52) is a DOT1L ligand. DOT1L ligand-2 acts as a Ligand for Target Protein for PROTAC, which is used to develop and design degraders of PROTAC DOT1L, such as DOT1L808 (HY-181789). DOT1L ligand-2 is applicable to research related to MLL-rearranged leukemia .
Cat. No.: HY-173424
CAS No.: 2768514-43-6
Research Areas:
E3 Ligase Ligand-linker Conjugate 178 is an E3 ligase ligand-linker conjugate. E3 Ligase Ligand-linker Conjugate 178 can be used to synthesize MS2133 (HY-173422) .
Cat. No.: HY-181789
Target:
Research Areas:
DOT1L808 is a potent and highly selective DOT1L PROTAC degrader with a DC50 value of 5 nM. DOT1L808 can promote the ubiquitination and degradation of DOT1L. DOT1L808 exhibits antitumor activity in an orthotopic leukemia model .
Cat. No.: HY-181787
CAS No.: 3050756-34-5
Target:
Research Areas:
DOT1L705 is a PROTAC degrader that targets DOT1L. DOT1L705 recruits the VHL E3 ubiquitin ligase to induce proteasomal degradation of DOT1L. DOT1L705 reduces the viability of leukemia cells. DOT1L705 inhibits H3K79 methylation. DOT1L705 can be used in studies related to MLL-rearranged leukemia .
Cat. No.: HY-181748
Research Areas:
VHL Ligand-Linker Conjugates 18 is an E3 ligase ligand-linker conjugate containing an E3 ligase ligand (HY-181791) and a linker. VHL Ligand-Linker Conjugates 18 can be used for the synthesis of PROTACs, such as DOT1L808 (HY-181789) .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
